文献速递艾滋病与性传播感染

罗米地辛作为HIV潜伏逆转剂的药代动力学/药效学分析

Pharmacokinetic/pharmacodynamic analysis of romidepsin used as an HIV latency reversing agent.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

本研究在15例HIV-1感染者中建立罗米地辛(5 mg/m2)群体药代动力学模型,评估暴露与病毒基因表达及抗病毒免疫的关系。罗米地辛药代动力学符合三室线性模型,体重影响其处置;AUC0-∞升高与CD4+和CD8+ T细胞耗竭标志物表达增加及CD4+细胞凋亡标志物相关,但与组蛋白乙酰化水平或HIV-1细胞相关RNA无关;AUC0-∞每增加100 ng·h/mL,CD4+计数平均下降74(95%CI 42-94)cells/mm3。

要点

  • 罗米地辛药代动力学符合三室线性模型,体重影响其处置。
  • AUC0-∞升高与T细胞耗竭和凋亡标志物增加相关,但不增加病毒再激活。
  • AUC0-∞每增加100 ng·h/mL,CD4+计数平均下降74(95%CI 42-94)cells/mm3。

核心结论

  • 较高罗米地辛暴露导致凋亡标志物表达升高和CD4+计数下降,但未增加病毒再激活水平。

研究设计与样本

  • 在BCN02临床试验中,对15例HIV-1感染者每周三次静脉输注罗米地辛(5 mg/m2)进行群体药代动力学分析。

主要发现

  • 罗米地辛药代动力学最佳描述为三室线性模型,体重影响其处置。
  • 罗米地辛AUC0-∞与CD4+和CD8+ T细胞耗竭标志物表达增加及CD4+细胞凋亡标志物相关。
  • 罗米地辛AUC0-∞与组蛋白乙酰化水平或CD4+ T细胞中HIV-1细胞相关RNA无关。
  • 罗米地辛AUC0-∞每增加100 ng·h/mL,给药后CD4+计数平均下降74(95%CI 42-94)cells/mm3。

临床怎么用

  • 优化HIV-1治愈的kick-and-kill策略时需考虑罗米地辛暴露与CD4+计数下降的关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To develop a population pharmacokinetic model for romidepsin given as an HIV latency reversing agent (LRA) and to explore the relationship between romidepsin exposure and its in vivo effects on viral gene expression and antiviral immunity. METHODS: A population pharmacokinetic analysis was performed in 15 HIV-1-infected patients who received three weekly infusions of romidepsin (5 mg/m2) within the BCN02 clinical trial. A full pharmacokinetic profile was obtained for each participant at the first dose, and additional samples thereafter. A population pharmacokinetic model was developed. Bayesian estimates of the individual pharmacokinetic parameters of romidepsin were used to simulate individual time-concentration curves on each occasion. The relationship between romidepsin AUC0-∞ and its in vivo effects was assessed. RESULTS: Romidepsin pharmacokinetics were best described by a three-compartment model with linear kinetics. Body weight influenced romidepsin disposition. A significant relationship was observed between romidepsin AUC0-∞ and increases in expression of exhaustion markers by CD4+ and CD8+ T cells and apoptosis markers in CD4+, but not with histone acetylation levels or HIV-1 cell-associated RNA in CD4+ T cells. For each increase of 100 ng·h/mL in romidepsin AUC0-∞, CD4+ counts decreased by a mean (95% CI) of 74 (42-94) cells/mm3 after dosing. CONCLUSIONS: A population model describing the pharmacokinetics of romidepsin as an HIV LRA was developed. Higher exposure to romidepsin resulted in higher expression of apoptosis markers and declines in CD4+ count but did not increase viral reactivation levels. These observations have important implications for the optimization of effective kick-and-kill strategies for an HIV-1 cure.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Moltó J, Rosás-Umbert M, Miranda C, et al. Pharmacokinetic/pharmacodynamic analysis of romidepsin used as an HIV latency reversing agent. J Antimicrob Chemother. 2021. PMID: 33367767. doi:10.1093/jac/dkaa523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。